Venetoclax and navitoclax after transplant for high-risk T-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding venetoclax and navitoclax around the time of an allogeneic stem cell transplant can help prevent relapse in people with high-risk T-ALL (or related T-cell blood cancers). It also looks at whether these medicines can be used after transplant to help keep the disease under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old when you sign the consent.
- Have a new diagnosis of T-ALL, T-LBL, or MPAL T/myeloid (according to WHO 2016).
- Be in your first complete response and your doctors plan an allogeneic stem cell transplant (alloSCT).
- Your initial cancer treatment must include a BFM-style induction with asparaginase (not a different induction style like HyperCVAD).
- Your blood and organ tests must be strong enough: platelets and neutrophils at set minimums, liver enzymes/bilirubin not too high, and kidney function (creatinine clearance) at least 30 mL/min.
- You must be able to use effective birth control and agree to pregnancy testing if you can become pregnant, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
This trial tests whether adding venetoclax (a pill) to a lower-intensity bone marrow or stem cell transplant, and continuing it after transplant, helps prevent acute myeloid leukemia (AML) from coming back. You may join if you are in first remission and have a suitable donor.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
This trial tests the combination of two drugs, venetoclax and decitabine, for people whose T-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatment. The goal is to see if this combo can help when other treatments haven't worked.
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.